Alembic Pharmaceuticals appoints Tushar Mehta as Head-R&D

1 min read Updated on 04 Jun 2026, 12:55 AM

Reviewed by

Jubin VScanX News Team

AI Summary

Alembic Pharmaceuticals Limited has appointed Mr. Tushar Mehta as the Head-R&D (API) effective June 3, 2026. He brings over 24 years of experience in API R&D, having led over 100 development programs and managed teams of 200 scientists.

*this image is generated using AI for illustrative purposes only.

Alembic Pharmaceuticals Limited has appointed Mr. Tushar Mehta as the Head-R&D (API), effective June 3, 2026. The appointment strengthens the company's senior management personnel structure. Mr. Mehta brings over 24 years of experience in Active Pharmaceutical Ingredient (API) research and development to the role.

Appointment Details

The appointment was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company disclosed that the term of appointment is full-time employment. The disclosure was read with Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026.

Professional Background

Mr. Tushar Mehta has led over 100 API development programs, with more than 45 successfully commercialized. His professional history includes building and directing an R&D team of 200 scientists. He has filed multiple US Drug Master Files (USDMFs) and has steered projects through US Food and Drug Administration (FDA) and European Medicines Agency (EMA) regulations.

His expertise encompasses small-molecule APIs, covering complex therapeutic areas such as oncology and antiviral products. Notable products in his portfolio include Remdesivir and Molnupiravir, along with statins and other advanced APIs.

Previous Roles

Prior to joining Alembic, Mr. Mehta served as SVP & Head – R&D (API) at Cadila Pharmaceuticals. He has also held R&D leadership roles at Piramal (O2h), Ami Life Sciences, and BDR Life Sciences.

Particulars	Details
Name	Mr. Tushar Mehta
Designation	Head-R&D (API)
Date of Appointment	June 3, 2026
Term of Appointment	Full-time employment
Experience	24+ years in API R&D
Previous Role	SVP & Head – R&D (API) at Cadila Pharmaceuticals

Historical Stock Returns for Alembic Pharmaceuticals

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+0.12%	-2.09%	-3.57%	-18.11%	-24.76%	-22.23%

How will Mr. Mehta's expertise in complex therapeutic areas like oncology influence Alembic's future R&D pipeline?

What is the expected timeline for the commercialization of new API projects under his leadership?

Could this appointment accelerate Alembic's regulatory approvals with the FDA and EMA?

Read Next Article

Alembic Pharmaceuticals restructures senior management reporting

1 min read Updated on 03 Jun 2026, 12:40 AM

Reviewed by

Riya DScanX News Team

Add as a preferred
source on Google

AI Summary

Alembic Pharmaceuticals restructured its internal reporting structure effective June 2, 2026, resulting in Mr. Atul Suri and Mr. Prag Goel ceasing to be Senior Management Personnel. They will now report to Mr. Ramesh Juneja, the newly appointed Executive Vice President – Human Health (Sales and Marketing), India Business.

*this image is generated using AI for illustrative purposes only.

Alembic Pharmaceuticals has restructured its internal reporting structure effective June 2, 2026, resulting in the cessation of Mr. Atul Suri and Mr. Prag Goel as Senior Management Personnel. The company stated that these executives will now report to Mr. Ramesh Juneja, the newly appointed Executive Vice President – Human Health (Sales and Marketing), India Business. This organizational change was disclosed to the stock exchanges pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Mr. Juneja, who assumed his role on June 1, 2026, brings over three decades of experience in pharmaceutical sales and marketing. A pharmacy graduate from Sant Gadge Baba Amravati University and an MBA holder from Symbiosis International University, he has previously held leadership positions at Sun Pharmaceutical Industries and Cipla. Prior to joining Alembic Pharmaceuticals , he founded the Ramesh Juneja Business Advisory and co-founded BJW Health Pvt. Ltd.

The changes in the senior management hierarchy are detailed in the table below:

Particulars	Details
Reason for change	Internal change in reporting structure / Ceased to be Senior Management Personnel
Date of effect	June 2, 2026
Designation of affected personnel	Senior Vice President - Sales & Marketing (Mr. Atul Suri), Vice President - Sales & Marketing (Mr. Prag Goel)
New reporting line	Mr. Ramesh Juneja, Executive Vice President – Human Health (Sales and Marketing)